Melissa Reimers, MD

Medical Oncologist

Melissa Reimers

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108
Siteman Cancer Center at Barnes-Jewish West County Hospital

Siteman Cancer Center at Barnes-Jewish West County Hospital

Medical Office Building 2, 10 Barnes West Drive, Creve Coeur, MO 63141

Expertise & Training

Video thumbnail for Dr. Melissa Reimers, MD

Watch video on YouTube

Dr. Melissa Reimers, MD

6 mins

Dr. Melissa Reimers, MD Associate Professor of Medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine at Siteman Cancer Center.

Clinical Expertise

  • Genitourinary oncology, prostate cancer, bladder cancer, kidney cancer.

Primary Academic Title

Associate Professor of Medicine, Division of Oncology, Section of Medical Oncology, WashU Medicine

Board Certification

  • 2016: American Board of Internal Medicine

Training

  • 2013 - 2016: Resident, Internal medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC
  • 2016 - 2019: Fellow, Hematology and Oncology, University of Michigan, Ann Arbor, MI

Education

  • 2013: MD, Saint Louis University, St. Louis, MO

Research & Selected Publications

Research Interest

Clinical trial development in genitourinary malignancies, primarily in prostate and bladder cancer, precision medicine in clinical trial design.

Research Publications

PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future
Authors:

Ayzman A, Pachynski RK, Reimers MA

Journal & Year:

Curr Treat Options Oncol | 2025

Tumour evolution and microenvironment interactions in 2D and 3D space
Authors:

Mo CK, Liu J, Chen S, one or more additional authors omitted Reimers MA, one or more additional authors omitted Ding L

Journal & Year:

Nature | 2024

Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Authors:

Nguyen CB, Reimers MA, Perera C, one or more additional authors omitted Alva AS

Journal & Year:

Clin Cancer Res | 2024